Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VentiRx Pharmaceuticals has completed the Phase 1 clinical study of its novel TLR8 agonist for oncology, VTX-2337.
Subscribe to our email newsletter
VTX-2337 was proven to be safe and well tolerated with a predictable pharmacokinetic profile in 33 patients. In addition, VTX-2337 showed dose-dependent pharmacologic activity, according to the study results presented at the International Society for Biological Therapy of Cancer (ISBTC).
The preclinical results indicate the combination of VTX-2337 and Doxil elicits potent immune responses in an ovarian cancer model and that further clinical testing is warranted.
Preclinical evaluation of VTX-2337 suggested that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology.
VentiRx plans to initiate a Phase 1b/2a trial in the near future.
VentiRx co-founder and chief medical officer Robert Hershberg said that when used in conjunction with chemotherapy, compounds like VTX-2337 have the potential to change the way we’ve traditionally approached difficult-to-treat cancers.